Prognostic value of computed tomography derived skeletal muscle mass index in lung cancer: A meta-analysis

Table 1 Basic characteristics of included studies

Ref.	Year	Country	Sample size	Treatment	TNM stage	Threshold of SMI (cm2/m2)	Tumor type	NOS
Jafri et al[20]	2015	United States	112	Non-surgery	IV	40	NSCLC	7
Suzuki et al[22]	2016	Japan	90	Surgery	I	Male: 43.75; female: 41.10	NSCLC	7
Sjøblom et al[21]	2016	Norway	734	Non-surgery	III-IV	NR	NSCLC	7
Shoji et al[24]	2017	Japan	147	Surgery	I	Male: 43.75; female: 41.10	NSCLC	7
Nattenmüller et al[23]	2017	Germany	200	Non-surgery	I-IV	NR	LC	7
Roch et al[28]	2020	France	142	Non-surgery	NR	Male: 52.4; female: 38.5	NSCLC	6
Abbass et al[25]	2020	United Kingdom	643	Non-surgery	III-IV	Male: 43; female: 41	LC	6
Dolan et al[26]	2020	United Kingdom	119	Non-surgery	I-III	Male: 53; female: 41	NSCLC	6
Magri et al[27]	2019	Israel	46	Non-surgery	IV	NR	LC	6
Katsui et al[29]	2021	Japan	60	Non-surgery	III	Male: 43; female: 24	NSCLC	7
Lee et al[30]	2021	Republic of Korea	70	Non-surgery	IIIB-IV	Male: 46; female: 29	SCC	6
Yang et al[31]	2021	China	639	Non-surgery	IIIB-IV	Male: 32.48; female: 27.82	NSCLC	7

TNM: Tumor-node-metastasis; SMI: Skeletal muscle mass index; NOS: Newcastle-Ottawa Scale; NR: Not reported; NSCLC: Non-small cell lung cancer; LC: Lung cancer; SCC: Squamous cell cancer.

Table 2 Results of meta-analysis

	No. of studies	HR	95%CI	P value	I2 (%)	P value
Overall survival	12	1.23	1.11-1.37	< 0.001	84.7	< 0.001
Treatment
Non-surgery	10	1.15	1.06-1.26	0.002	80.4	< 0.001
Surgery	2	5.71	2.94-11.10	< 0.001	0.0	0.655
Tumor stage
Advanced stage	7	1.34	1.07-1.68	0.011	80.8	< 0.001
Early stage	2	5.71	2.94-11.10	< 0.001	0.0	0.655
Tumor type
Non-small cell lung cancer	9	1.97	1.33-2.93	0.001	87.3	< 0.001
Lung cancer	3	1.07	1.03-1.11	< 0.001	0.0	0.471

HR: Hazard ratios; CI: Confidence interval.